Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2 - Higuchi, Yusuke; Suzuki, Tatsuya; Arimori, Takao; Ikemura, Nariko; Mihara, Emiko; Kirita, Yuhei; Ohgitani, Eriko; Mazda, Osam; Motooka, Daisuke; Nakamura, Shota; Sakai, Yusuke; Itoh, Yumi; et al. (Nature communications, 2021)
Keywords: 42/70; 49/31; 631/154/51/1568; 631/326/596/4130; 82/1; 82/103; 82/47; 82/80; 82/83; ACE2; Affinity; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - genetics; Angiotensin-Converting Enzyme 2 - metabolism; Angiotensin-Converting Enzyme 2 - pharmacology; Animals; Binding; Cells, Cultured; Conformation; COVID-19; COVID-19 - metabolism; COVID-19 - virology; COVID-19 Drug Treatment; Cricetinae; Crystallography, X-Ray; Disease Models, Animal; Hamsters; Humanities and Social Sciences; Humans; Hydrogen bonding; Hydrophobicity; Male; Molecular Dynamics Simulation; multidisciplinary; Mutagenesis; Mutation; Pandemics; Protein Binding; Protein Engineering - methods; Random mutagenesis; Receptors; SARS-CoV-2 - drug effects; SARS-CoV-2 - isolation & purification; SARS-CoV-2 - metabolism; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - metabolism; Structural stability; Therapeutic applications; Viral diseases; Viruses